Apricitabine

Summary

Apricitabine (CHEMBL210651) is a phase-3 clinical-stage small molecule; indicated across 1 condition including hiv infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 5
• Chemistry: 229.26 Da · C8H11N3O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL210651
Name	Apricitabine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	455041
Molecular formula	C8H11N3O3S
Molecular weight	229.26
InChIKey	RYMCFYKJDVMSIR-RNFRBKRXSA-N

SMILES: C1[C@@H](S[C@@H](O1)CO)N2C=CC(=NC2=O)N

IUPAC name: 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one

Also known as: Apricitabina, Apricitabine, AVX-754, BCH-10618, BCH-10652, (-)-, SPD -754, SPD-754, SPD754, (-)2’-deoxy-3’-oxa-4’-thiocytidine, APRICITABINE, apricitabine

Patent coverage: 466 distinct patent families (1,279 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
HIV infectious disease	3	MONDO:0005109	EFO:0000764

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	2
PHASE2/PHASE3	1
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00612898	PHASE2/PHASE3	TERMINATED	Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
NCT00686270	PHASE3	WITHDRAWN	A Long Term Safety Study of Apricitabine in HIV-infected Patients
NCT00367952	PHASE2	COMPLETED	A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
NCT00334659	PHASE1	COMPLETED	A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
NCT00352066	PHASE1	COMPLETED	Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).